Skip to Content

'
Wen-Jen Hwu, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Consulting Attending, Lyndon B. Johnson General Hospital-Internal Medicine Medical Oncology, Houston, TX

Education & Training

Degree-Granting Education

1982 University of California College of Medicine, Irvine, CA, MD, Medicine
1976 Carnegie-Mellon University, Pittsburgh, PA, PHD, Chemistry
1971 National Tsinghua University, Hsinchu, Taiwan, BS, Chemistry

Postgraduate Training

7/1986-6/1989 Postdoctoral Fellowship in Medical Oncology, Yale University School of Medicine, Section of Medical Oncology, Department of Internal Medicine, New Haven, CT
6/1982-6/1985 Internship and Residency in Internal Medicine, University of California College of Medicine, UCI Medical Center, Orange, CA

Board Certifications

1989 American Board of Medical Oncology
1985 American Board of Internal Medicine

Experience/Service

Institutional Committee Activities

Member, Graduate Faculty, Graduate School of Biomedical Sciences, Health Science Center at Houston, The University of Texas, Houston, Tx, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8(4):493-9, 7/2009. PMID: 19435405.
2. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson NN, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 19(1):42-9, 2/2009. PMID: 19430405.
3. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz PJ, Vernillet L, Hwu P. A phase 1B trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage III or stage IV melanoma. Cancer Invest 27(7):756-63, 2009. PMID: 19440934.
4. Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol 64(1):161-7, 2009. PMID: 19002462.
5. Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, von Althann C, Lamb LA, Alvarado G, Bilsky MH, Gutin PH. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 10(2):199-207, 4/2008. e-Pub 2/2008. PMID: 18287337.
6. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jackowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE. Randomized trial of an allogenic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 25(15):2078-85, 5/2007. PMID: 17513813.
7. Yeh JJ, Shia J, Hwu WJ, Busam KJ, Paty PB, Guillem JG, Coit DG, Wong WD, Weiser MR. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Annals Surg 244(6):1012-7, 12/2006. PMID: 17122627.
8. Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG; Cancer and Leukimia Group B. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107(8):1883-90, 10/2006. PMID: 16986123.
9. Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II study of temozolomide plus pegylated interferon- alpha-2b for metastatic melanoma. Cancer 106(11):2445-51, 6/2006. PMID: 16639739.
10. Hwu WJ. Temozolomide plus pegylated interferon-alpha-2b in patients with metastatic melanoma. Am J Hematol Oncol 5:680-3, 2006.
11. Thompson MA, Warner NB, Hwu WJ. Hypertrophic osteoarthropathy associated with metastatic melanoma. Melanoma Res 15(6):559-61, 12/2005. PMID: 16314744.
12. Yeh JJ, Weiser MR, Shia J, Hwu WJ. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol 6(6):438-9, 6/2005. PMID: 15925823.
13. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103(12):2590-7, 6/2005. PMID: 15861414.
14. Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 10(14):4717-23, 7/2004. PMID: 15269144.
15. Lohmann CM, Hwu WJ, Iversen K, Jungbluth AA, Busam KJ. Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens. Melanoma Res 13(6):595-601, 12/2003. PMID: 14646623.
16. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 9(14):5214-20, 11/2003. PMID: 14614001.
17. Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21(17):3351-6, 9/2003. PMID: 12947072.
18. Busam KJ, Sachs DL, Coit DG, Halpern A, Hwu WJ. Eruptive melanotic macules and papules associated with adenocarcinoma. J Cutan Pathol 30(7):463-9, 8/2003. PMID: 12859746.
19. Chapman, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 22(21-22):2904-9, 7/2003.
20. Wolchok JD, Williams L, Pinto JT, Fleisher M, Krown SE, Hwu WJ, Livingston PO, Chang C, Chapman PB. Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res 13(2):189-96, 4/2003. PMID: 12690304.
21. Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, Hwu WJ. Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma Res 12:381-7, 8/2002. PMID: 12170188.
22. Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 20(11):2610-5, 6/2002. PMID: 12039921.
23. Berwick, Song Y, Roy P, Mahabir S, Elahi A, Coit D, Lewis J, Halpern A, Myskowski P, Brady M, Hwu WJ, Chapman PB, Livingston PL, Polsky D. Association of DNA damage/repair deficiency with melanoma. J Investigative Dermatology 114(4):847, 2002.
24. Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol 2:634-5, 10/2001. PMID: 11902555.
25. Pollak JS, Burdge CM, Rosenblatt M, Houston JP, Hwu WJ, Murren J. Treatment of malignant pleural effusions with tunneled long-term drainage catheters. J Vasc Interv Radiol 12(2):201-8, 2/2001. PMID: 11265884.

Last updated: 9/1/2009